Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
110.99
+2.50 (2.30%)
Aug 12, 2026, 2:38 PM EDT - Market open
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $761.00K in the quarter ending June 30, 2026, with 294.30% growth. This brings the company's revenue in the last twelve months to $1.90M, down -60.77% year-over-year. In the year 2025, Dianthus Therapeutics had annual revenue of $2.04M, down -67.35%.
Revenue (ttm)
$1.90M
Revenue Growth
-60.77%
P/S Ratio
3,260.88
Revenue / Employee
$20,696
Employees
92
Market Cap
6.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | -4.20M | -67.35% |
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Caris Life Sciences | 989.61M |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| Ligand Pharmaceuticals | 290.54M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 6.23M |
DNTH News
- 6 days ago - Dianthus price target raised to $128 from $110 at Truist - TheFly
- 6 days ago - Dianthus price target raised to $158 from $130 at H.C. Wainwright - TheFly
- 7 days ago - Dianthus price target raised to $122 from $105 at Wedbush - TheFly
- 7 days ago - Dianthus reports Q2 EPS (90c), consensus (91c) - TheFly
- 7 days ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results - GlobeNewsWire
- 7 days ago - Dianthus Therapeutics Earnings release: Q2 2026 - Filings
- 7 days ago - Dianthus Therapeutics Quarterly report: Q2 2026 - Filings
- 8 days ago - Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases - GlobeNewsWire